Treatment of HER2+/ER–/AR+ BC cells (LAR-BC cells), MDA-MB453, with DHT stimulates cell growth by activating the oncogenic Wnt and the HER3 signaling pathway. This evidence concerns the gene ERBB3 and breast cancer.